Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer

Table 4

Clinical trials of adjuvant endocrine therapy in elderly patients with breast cancer.

Study	Design	Number of patients	Treatment	Primary end point	Results
ATAC [11]	Phase 3, randomized	9366	Anastrozole 1 mg versus tamoxifen 20 mg versus anastrozole 1 mg + tamoxifen 20 mg	DFS	A versus T; HR 0.91, 95% CI 0.83–0.99	0.04
BIG 1-98 [12]	Phase 3, randomized, double-blind	8010	T-L versus letrozole; L-T versus letrozole	DFS	HR 1.05, 99% CI 0.84–1.32; HR 0.96, 99% CI 0.76–1.21
MA. 17 [13]	Phase 3, randomized, double-blind	5187	Tamoxifen-letrozole versus tamoxifen-placebo	DFS	HR 0.58, 95% CI 0.45–0.76	<0.001

No, number; DFS, disease-free survival; A, anastrozole; T, tamoxifen; HR, hazard ratio; CI, confidence interval; L, letrozole.